Kornimate/medical-research-clean huggingface dataset:
monitoring of the iop after slt using icare home

Conditions: Glaucoma Open-Angle Primary; Pseudo Exfoliation Syndrome

Summary: the purpose of this study is to investigate how much selective trabeculoplasty (slt) influences intraocular pressure (iop) fluctuations measured with icare home rebound tonometry (rthome) in patients with primary open-angle glaucoma (poag) or pseudo-exfoliation glaucoma (pex).

sixty glaucoma patients (poag and pex) planned for slt will be recruited. at baseline, patients will be trained to use the icare home tonometer, a handheld device based on rebound tonometry and designed for patients to use at home. after the training session and when patients feel confident, a measurement will be recorded. thereafter, a new measurement will be obtained by the study staff (an optometrist or a nurse) using the same device. no iop values will be visible for the examiner at that point. thereafter, a single iop measurement will be obtained by the same study staff using goldmann applanation tonometry (gat). patients will then borrow the icare home tonometer to meaure their iop at 06 and 10 am, and at 2, 6 and 10 pm during three consecutive days to obtain an iop curve. patients will come for a second visit where new measurements will be made in the same way as at baseline. two months after slt, a new iop curve will be obtained following the same procedure as pre-operatively. patients' daily activities (diet, motion or sleeping habits) will not be controlled.

Eligibility criteria:
inclusion criteria: * poag * pxg exclusion criteria: * previous slt * reduced hand and arm mobility (e.g. due to rheumatism)

Keywords: iop fluctuations icare home slt self-tonometry
a novel index for tissue perfusion in predicting outcome in patients with septic shock

Conditions: Septic Shock

Summary: septic shock is a life-threatening condition with mortality rate of up to -40%. septic shock is catheterized by altered microcirculation that leads to tissue hypoperfusion and ultimately multi-organ dysfunction. hence, maintenance of adequate tissue perfusion is the mainstay of resuscitation of patients with septic shock. serum lactate is still considered the gold standard for evaluation of tissue perfusion. thus, according to the latest definition, elevated serum lactate, as an indicator of tissue hypo-perfusion, is required for diagnosis of septic shock. however, lactate level change in response to resuscitation is slow even in survivors. capillary refill time (crt) is a simple method for assessing peripheral perfusion. monitoring crt was found to be a good tool for guiding resuscitation and delayed crt showed good ability in predicting mortality in patients with septic shock. to the best of our knowledge, there is no previous report assessing the reliability of an index that include both serum lactate and crt (lactate/crt index) in predicting mortality in patients with septic shock. we hypothesize that the lactate/crt index would have good accuracy in predicting mortality in patient with septic shock.

all patients will be monitored with; non-invasive and invasive arterial blood pressure, five-lead electrocardiography (ecg), hourly urinary output, and central venous pressure (cvp). management of the patients will be done according to the latest surviving sepsis campaign guidelines in 2016. apache ii score will be calculated on the time of admission using mdcalc ©. arterial blood gases, including serum lactate (blood gas analysis device gem premier 300, instrumentation laboratory, bedford, ma, usa), will be obtained at the time of intensive care unit admission, 6 and 12 hours after admission. capillary refill time will be measured by applying enough pressure to cause skin blanching to the ventral surface of the distal phalanx of right index finger and the pressure will be then maintained for 10 seconds. the time for return of the normal skin color will be registered with a stopwatch. crt will be recoded at the same time point as the blood sample. the change in serum lactate (∆ lactate), and crt (∆ crt) will be calculated as the difference between each two-consecutive measurement. lactate/crt index will be calculated as the product of multiplying the crt and serum lactate.

Eligibility criteria:
inclusion criteria: * patients with clinically suspected septic shock, older than 18 years old exclusion criteria: * patients less than 18 years. * patients with evident blood loss. * patients with metastatic cancer. * patients with child b or c liver cirrhosis * patients with estimated glomerulo filtartion rate less than 30 ml/min/m2
adherence in adolescents and children treated on quetiapine

Conditions: Psychosis

Summary: observational study aimed to describe the adherence in a population of adolescents and children treated on quetiapine from a first psychotic episode whose more important secondary objective is to identify possible predictive factors influencing the adherence to treatment with quetiapine


Eligibility criteria:
inclusion criteria: * at least one psychotic symptom (delusions or hallucinations) before age 18. * start of treatment in a maximum period of 2 years after the onset of first psychotic symptom * written informed consent by parents or guardians and patients. exclusion criteria: * pregnancy or lactancy * high risk of aggression or suicidal behaviour * alcohol dependence

Keywords: psychosis adolescents adherence quetiapine
preventing malaria in school children to protect the whole community in rural blantyre district, malawi

Conditions: Malaria,Falciparum; Anemia in Children

Summary: this is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies arm 1: intermittent preventive treatment with dihydroartemisinin-piperaquine (ipt-dp). arm 2: intermittent preventive treatment with sulfadoxine-pyrimethamine (sp) plus amodiaquine (aq) (ipt-spaq). arm 3: control - students will receive standard of care (no preventive treatment). outcomes include p. falciparum infection and parasite density, anemia, cognitive function and educational testing, as well as infection prevalence and disease incidence in young children sleeping student's households to assess the impact on transmission.

students attending primary school in rural blantyre district, malawi will be offered enrollment in this study. the intervention will be conducted every 6-weeks during the school terms which coincide with peak malaria transmission. students in the ipt-dp arm will be treated with with dihydroartemisinin-piperaquine (dp) (females less than 13 years old and all males) or chloroquine (females 13 years old or older). students in the ipt-spaq arm will be treated with sulfadoxine-pyrimethamine plus amodiaquine (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older). students in the all arms will receive routine malaria education.

Eligibility criteria:
student inclusion criteria: * currently enrolled in the study school * plan to attend the study school for the remainder of the school year * parent/guardian available to provide written informed consent student exclusion criteria: * current evidence of severe malaria or danger signs * known adverse reaction to the study drugs * history of cardiac problems or fainting * taking medications known to prolong qt * family history of prolonged qt * history of epilepsy or psoriasis * taking cotrimoxazole for long-term prophylaxis younger child inclusion criteria * slept in the household for most nights in the last month * age 6-59 months * parent/guardian available to provide written informed consent younger child exclusion criteria - current evidence of severe malaria or danger signs

Keywords: iptsc school chemoprevention intermittent preventive treatment malaria transmission
a neurofeedback booster for emotion regulation therapy

Conditions: Borderline Personality Disorder

Summary: this is a proof-of-concept study that aims to test the additional value of adjuvant neurofeedback treatment for psychotherapy. three sessions of real-time fmri neurofeedback will be administered to n=22 patients with bpd while they receive residential dialectical behavior therapy treatment. in addition, outcomes are assessed from a control group with same sample size who do not receive the treatment.


Eligibility criteria:
inclusion criteria: * dsm-5 bpd diagnosis * informed consent * etoh and tox negative on the day of neurofeedback * bsl-23 score \>=1.87 at dbt halftime exclusion criteria: * pharmacotherapy with opiates * standing benzodiazepines (bedtime-only benzodiazepines and anti-histamines allowed) * pregnancy * epilepsy * life-time diagnosis schizophrenia or bipolar disorder i * significant current or past neurological illness * bmi\<16.5 * usual safety criteria for magnetic resonance imaging
thrive feasibility trial

Conditions: Surgery--Complications; Anesthesia Complication; Anesthesia Awareness; Anesthesia Emergence Delirium; Anesthesia; Surgery; Quality of Life; Pain, Postoperative; Nausea, Postoperative; Anesthesia Morbidity; Depression; Sleep Disorders, Circadian Rhythm

Summary: to evaluate the feasibility of a pragmatic, large scale, comparative effectiveness, randomized evaluation of patient experience of intravenous propofol versus inhaled volatile anesthesia.

two-center single-blinded randomized feasibility study, with randomization 1:1 to either propofol tiva or inhaled volatile general anesthesia for patients who are receiving elective non-cardiac surgery. patients will be stratified by clinical site with 150 participants per site.

Eligibility criteria:
inclusion criteria: * 18 years or older * undergoing elective non-cardiac surgery expected to last ≥ 60 min requiring general anesthesia, including a tracheal tube or laryngeal mask airway (or similar supra-glottic device) exclusion criteria: * inability to provide informed consent in english * pregnancy (based on patient report or positive test on the day of surgery) * surgical procedure requiring general, regional, neuraxial anesthesia administered by an anesthesia clinician (anesthesiologist, crna, anesthesiology assistant) occurring within 30 days prior to or planned to occur within 30 days after surgery date * contraindication to propofol tiva or inhaled volatile (for example, documented allergy to propofol, history of severe postoperative nausea or vomiting, concern for or history of malignant hyperthermia) * surgical procedures requiring specific general anesthesia option (for example, tiva required for neuromonitoring). * hospital approved, written protocol mandating a particular technique * history of intraoperative awareness during general anesthesia based on patient self-report on the day of consent * planned postoperative intubation

Keywords: quality of recovery intraoperative awareness
jak2 mutation may predict response and guide first line treatment in rheumatoid arthritis

Conditions: Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression

Summary: this study included 76 newly diagnosed ra patients and 50 matched controls. basal jak2 mutation was assessed by pcr in blood samples, tnf-α and il 6 were measured by elisa in serum of patients and controls. all patients started therapy with conventional synthetic dmards (including methotrexate). response assessment at 3rd month was evaluated by das28 and acr response criteria. jak2 mutation was correlated with different clinical and laboratory parameters of patients.

pcr detection of the jak-2 v617f mutation using aso specific pcr genetic marker: the detection of jak2 v617f mutation were done by using the following primers (jak2 reverse: 5' ctgaatagtcctacagtgttttcagtttca 3', jak2 forward (specific): 5' agcatttggttttaaattatggagtatatt 3' and jak2 forward (internal control): 5' atctatagtcatgctgaaagtaggagaaag 3'). cycling conditions were 35 cycles with annealing temperature 58.5oc flowed by agarose gel 2% electrophoresis for bands detections. all patients started treatment by conventional synthetic dmards (including methotrexate). response assessment at 3rd month was evaluated by das28 and acr response criteria. jak2 mutation was correlated with different clinical and laboratory parameters of patients. the disease activity score (das) and the das28 have been developed to measure disease activity in ra both in daily clinical practice as well as in clinical trials on a group as well as individual level. the das/das28 is a continuous measure of ra disease activity that combines information from swollen joints, tender joints, acute phase response and general health the das28 is a measure of disease activity in rheumatoid arthritis (ra). das stands for 'disease activity score' and the number 28 refers to the 28 joints that are examined in this assessment. questionnaires (e.g. the haq which assesses function), x-rays, and newer imaging techniques such as ultrasound and mri. the acr20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often health assessment questionnaire (haq)\], visual analog pain scale, and erythrocyte sedimentation rate or c-reactive protein (crp). acr50 and acr70 are the same instruments with improvement levels defined as 50% and 70% respectively versus 20% for acr20.

Eligibility criteria:
inclusion criteria: * new case ra patients * good liver and renal function exclusion criteria: * other autoimmune diss * malignancy * active viral infection * pregnancy and lactation
to evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures

Conditions: Seizure Disorder, Partial

Summary: to evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.


Eligibility criteria:
inclusion criteria: * must have met the inclusion criteria for the preceding double-blind study * have received double-blind study medication and wish to receive open-label pregabalin. exclusion criteria: * cannot have absence seizures.
serum calprotectin in surgical septic patients

Conditions: Infection, Intraabdominal; Sepsis Abdominal; Biomarker

Summary: to early evaluate the serum levels of calprotectin in patients suffering from intra-abdominal sepsis requiring a surgical treatment. the research project aims to investigate the role of serum calprotectin in the diagnosis of sepsis and to establish whether its level significantly correlates with different degree of disease severity and with short and long-term outcomes. if these associations were confirmed, serum calprotectin would represent an easily and rapidly detectable biomarker able to predict the severity of sepsis.

inclusion criteria are age\>18 years; diagnosis of upper/lower gastro-intestinal perforation, intestinal occlusion, acute cholecystitis, acute appendicitis or intra-abdominal sepsis. enrolled patients will be divided in two groups according to the calgary piro (cpiro) score evaluation: group a includes patients with cpiro score \ /= 3, therefore representing patients with more severe systemic forms. the control group (group c) will be made by elective surgical adult patients. a blood sample will be collected in sample tubes without anticoagulant from all the eligible patients at admission. after centrifugation, the serum will be stored at -80°c until analysis. the serum level of calprotectin will be measured using a commercially available elisa kit based on polyclonal antibodies, according to the manufacturer instruction and fully blinded to any clinical data of the patients or controls. to our knowledge, this is going to be the first study comparing the levels of serum calprotectin in a large cohort of surgical patients with different degree of intra-abdominal sepsis. our primary outcome is to determine whether the serum calprotectin level at the admission is increased in septic patients compared to the control group. we will correlate serum calprotectin level with pct levels, to check which is the most accurate for the detection of sepsis. our secondary outcome is to analyze if serum calprotectin level at admission correlates with the clinical severity of sepsis, evaluated trough the cpiro score. finally, we will verify if calprotectin level at admission is predictive of short and long-term morbidity and mortality, need for icu admission and invasive/non-invasive post-operative reinterventions.

Eligibility criteria:
inclusion criteria: * diagnosis of upper/lower gastro-intestinal perforation * diagnosis of intestinal occlusion * diagnosis of acute cholecystitis * diagnosis of complicated acute appendicitis * radiological diagnosis of intra-abdominal sepsis exclusion criteria: * recent (\<3 months) surgery * recent (\<3 months) trauma * diagnosis of acute pancreatitis * diagnosis of burn

Keywords: serum calprotectin surgical infections
dual-task training with different priority instructional sets on the gait parameters in patients with chronic stroke

Conditions: Stroke; Middle Cerebral Artery Stroke; Chronic Stroke

Summary: balance is controlled through a complex process involving sensory, visual, vestibular and cerebral functioning which get affected by various neurological disorders such as in stroke. different types of exercises are designed to target to cope up with the imbalance developed due to these neurological disorders. this study aimed to compare the efficacy of dual-task training using two different priority instructional sets in improving gait parameters such as self-selected velocity, fast speed, step length, and stride length in chronic stroke patients.

balance is controlled through a complex process involving sensory, visual, vestibular and cerebral functioning which get affected by various neurological disorders such as in stroke. different types of exercises are designed to target to cope up with the imbalance developed due to these neurological disorders. this study aimed to compare the efficacy of dual-task training using two different priority instructional sets in improving gait parameters such as self-selected velocity, fast speed, step length, and stride length in middle cerebral artery chronic stroke patients. a total of thirty middle cerebral artery chronic stroke patients were recruited on the basis of inclusion and exclusion criteria and equally allocated into two groups. group 1 received dual-task training with fixed priority instructional sets for four weeks and group 2 received dual-task training with variable priority instructional sets for four weeks. the outcome was assessed using a 10-meter walk test and the comparison of footprints on the walkway paper before and after training.

Eligibility criteria:
inclusion criteria: * a diagnosed case of middle cerebral artery chronic stroke made by a neurologist and verified using ct/mri * exhibited the age between 45 and 65 years * ability to walk 10 meters without assistance * their stroke onset within 12 months prior to the study and * scored greater than 24 on mini-mental state examination (mmse). exclusion criteria: * participants had neurological conditions other than stroke * uncontrolled hearing or visual and vestibular impairment * took more than 15 seconds on timed up \& go (tug) test * had lower extremity amputation * a case of diagnosed speech-language impairment (not able to respond verbally to auditory stimuli) by a speech-language pathologist and noticed their concurrent participation in another clinical trial

Keywords: stroke gait velocity stride length step length balance training dual task institutional priority sets
effect of debridement-scaling on the relief of dry eye signs and symptoms in sjogren's syndrome

Conditions: Sjogren's Syndrome

Summary: sjogren's syndrome is an autoimmune condition in which the body attacks its own glands in the body. some of these glands are responsible for providing lubrication for the eye. as a result, individuals with sjogren's syndrome often experience dry eye. recently, a study had shown that dry eye symptoms were improved by removing debris and old skin cells along the eyelid margin. this technique is called eyelid debridement-scaling. the purpose of this study is to determine how well this technique works in improving dry eye signs and symptoms in individuals with sjogren's syndrome.


Eligibility criteria:
inclusion criteria: * is at least 17 years of age and has full legal capacity to volunteer; * has read and signed an information consent letter; * is willing and able to follow instructions and maintain the appointment schedule; * is diagnosed with sjogren's syndrome; * meibomian gland score of ≤ 9 (out of 15); * osdi ≥ 23; * willing to maintain the use of otc medications throughout the course of the study * have not worn contact lenses within the past 3 years exclusion criteria: * is participating in any concurrent clinical or research study; * has any known active\* ocular disease and/or infection; * has a systemic condition, other than sjogren's syndrome and its associated conditions, that in the opinion of the investigator may affect a study outcome variable; * is using any systemic or topical medications, other than those indicated for sjogren's syndrome and its associated conditions, that in the opinion of the investigator may affect a study outcome variable; * has known sensitivity to the diagnostic pharmaceuticals to be used in the study; * is pregnant, lactating or planning a pregnancy at the time of enrolment; * is aphakic; * has undergone refractive error surgery; \* for the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
safety and efficacy of mt-1303 in subjects with moderate to severe active crohn's disease

Conditions: Crohn's Disease

Summary: the primary objectives of the study are: * to evaluate the safety and tolerability of mt-1303 in subjects with moderate to severe active crohn's disease（cd） * to evaluate the clinical efficacy of mt-1303 in subjects with moderate to severe active cd.


Eligibility criteria:
inclusion criteria: * diagnosis of cd (involving small intestine and/or colon), confirmed by both endoscopy and histopathology at least 3 months prior to visit 1 * previous use of any type of corticosteroids or immunosuppressants for the treatment of cd * moderate to severe active cd defined by a cdai score of ≥220 to ≤450 points at visit 1 exclusion criteria: * diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis or coeliac disease * enterocutaneous, abdominal or pelvic active fistulae, abscesses or fistulae likely to require surgery during the study * gi surgery (including appendectomy) within 12 weeks prior to visit 2 (baseline) or has surgery planned or deemed likely to require surgery for cd during the study

Keywords: crohn's disease